ArticleDiabetes care2017

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.

Vanita R Aroda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.